IRIS
D'AMICO, EMANUELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.808
EU - Europa 3.560
AS - Asia 2.655
Continente sconosciuto - Info sul continente non disponibili 772
SA - Sud America 744
AF - Africa 60
OC - Oceania 14
Totale 11.613
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.695
IE - Irlanda 1.245
SG - Singapore 1.226
RU - Federazione Russa 643
BR - Brasile 607
IT - Italia 527
HK - Hong Kong 423
SE - Svezia 393
CN - Cina 381
VN - Vietnam 287
FR - Francia 239
DE - Germania 163
FI - Finlandia 104
GB - Regno Unito 74
BD - Bangladesh 72
CA - Canada 54
AR - Argentina 52
IN - India 43
IR - Iran 43
ES - Italia 36
EC - Ecuador 33
MX - Messico 30
NL - Olanda 30
IQ - Iraq 29
PL - Polonia 29
TR - Turchia 28
ID - Indonesia 22
ZA - Sudafrica 16
JP - Giappone 15
AT - Austria 14
PK - Pakistan 13
AU - Australia 12
CO - Colombia 12
CR - Costa Rica 11
EG - Egitto 11
PY - Paraguay 11
SA - Arabia Saudita 10
VE - Venezuela 10
MA - Marocco 9
BE - Belgio 8
CL - Cile 8
UZ - Uzbekistan 8
CH - Svizzera 7
UA - Ucraina 7
AE - Emirati Arabi Uniti 6
KZ - Kazakistan 6
OM - Oman 6
DO - Repubblica Dominicana 5
NP - Nepal 5
RO - Romania 5
UY - Uruguay 5
DZ - Algeria 4
GR - Grecia 4
HU - Ungheria 4
JM - Giamaica 4
JO - Giordania 4
KE - Kenya 4
PE - Perù 4
PH - Filippine 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
CI - Costa d'Avorio 3
CZ - Repubblica Ceca 3
LB - Libano 3
LT - Lituania 3
PS - Palestinian Territory 3
PT - Portogallo 3
TN - Tunisia 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
DK - Danimarca 2
GA - Gabon 2
HN - Honduras 2
HR - Croazia 2
IL - Israele 2
KW - Kuwait 2
MD - Moldavia 2
MK - Macedonia 2
PA - Panama 2
QA - Qatar 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BG - Bulgaria 1
BW - Botswana 1
ET - Etiopia 1
GE - Georgia 1
KG - Kirghizistan 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MY - Malesia 1
NE - Niger 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
RS - Serbia 1
Totale 10.837
Salva come PNG Salva come JPEG
Città #
Dublin 1.242
San Jose 969
Chandler 491
Singapore 437
Hong Kong 413
Nyköping 327
Ashburn 326
Beijing 185
Santa Clara 183
Council Bluffs 173
Lauterbourg 148
Princeton 134
Ho Chi Minh City 106
Wilmington 85
Helsinki 82
São Paulo 58
Columbus 56
Munich 55
Frankfurt am Main 48
Hanoi 42
Los Angeles 41
Dallas 40
Rome 39
New York 36
Milan 35
Des Moines 32
Moscow 26
Shiraz 26
Bari 24
Naples 24
Hillsboro 23
Warsaw 23
Turku 22
Ann Arbor 21
Nuremberg 21
Rio de Janeiro 21
Seattle 21
Orem 20
Serra de' Conti 20
London 19
Brooklyn 16
Curitiba 15
Montreal 15
Paris 15
Tokyo 14
Assago 13
Granada 13
Thái Bình 13
Brasília 12
Chicago 12
Foggia 12
Guangzhou 12
Bexley 11
Denver 11
Falkenstein 11
Palermo 11
Phoenix 11
Quito 11
San José 11
Belo Horizonte 10
Biên Hòa 10
Düsseldorf 10
Mexico City 10
San Francisco 10
The Dalles 10
Cedar Knolls 9
Karachi 9
Ninh Bình 9
Shanghai 9
Toronto 9
Washington 9
Atlanta 8
Baghdad 8
Campinas 8
Can Tho 8
Da Nang 8
Kocaeli 8
Madrid 8
Porto Alegre 8
Stockholm 8
Boston 7
Buenos Aires 7
Guayaquil 7
Jiaxing 7
Riyadh 7
St Louis 7
Tehran 7
Vienna 7
Amsterdam 6
Cairo 6
Chennai 6
Fortaleza 6
Guarulhos 6
Houston 6
Hải Dương 6
Johannesburg 6
Juiz de Fora 6
Melbourne 6
Pune 6
Santo André 6
Totale 6.647
Salva come PNG Salva come JPEG
Nome #
La sindrome disesecutiva nel Mild Cognitive Impairment: aspetti clinici e possibilità riabilitative 243
Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 118
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 113
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 113
CCSVI and MS. A population-based case-control study in Catania, Sicily 112
Approccio clinico e possibilità di trattamento nella SLA 112
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 106
An update on the pharmacological management of pain in patients with multiple sclerosis 105
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update 101
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 100
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 99
Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV IgG Tests in RRMS to Assess PML Risk 99
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 99
Morfometria delle strutture del tronco encefalico in pazienti affetti da atassia spino-cerebellare tipo 2 (SCA 2): indicatore diagnostico e riabilitativo? 98
Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives 98
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 97
Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal 96
Association between dietary intake and function in amyotrophic lateral sclerosis 94
Can new chemical therapies improve the management of multiple sclerosis in children? 93
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 93
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 93
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 92
Clinical Evolution of Relapsing Remitting Late Onset Multiple Sclerosis: A Nine Year Follow-Up Study 91
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 91
Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders 91
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 90
Comparison of Two Therapeutic Strategies in Active Relapsing-Remitting MS: Cyclophosphamide as Induction for 12 Months Follewed by Interferon Beta Versus Interferon Beta. A Two-Year Randomized Trial 90
Review: Patient-reported outcomes in multiple sclerosis care 90
Dysphagia in Multiple Sclerosis 89
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 89
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 89
Psychological and social findings of patients with early multiple sclerosis or clinically isolated syndrome 88
Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy 88
Long term follow-up of combination therapy with inf-eta and cyclophosphamide relapsing-remitting MS patients 87
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 87
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 87
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 87
The Dysphagia in Multiple Sclerosis Questionnaire Correlates with Fiber-Optic Endoscopic Examination for Detecting Swallowing Deficits in MS 86
Use of a low-cost, commercially available gaming console (Nintendo-WII) foe rehabilitation of patients with multiple sclerosis: results of a pilot study 85
Employment status in MS patients: a population-based study 85
The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 85
A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis 84
An update on the safety of treating relapsing-remitting multiple sclerosis 84
Prevalence and Incidence of Multiple Sclerosis in the City of Biancavilla 84
Neuropsychological pattern of cognitive dysfunction in clinically isolated syndrome suggestive of MS 83
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 83
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience 82
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 82
Effects of inpatient and outpatient rehabilitation setting on disability and quality of life of patients with multiple sclerosis: a randomized controlled study 81
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis 81
The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study 80
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study 80
Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS 79
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 79
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 78
First-line therapies in Late Onset Multiple Sclerosis: an Italian registry study 77
Cognitive dysfunction in multiple sclerosis. A population based study in Catania, Sicily 77
Negative prognostic impact of spinal demyelinating lesions at clinical onset in relapsing-remitting multiple sclerosis 77
Unsatisfactory clinical and MRI response to DMTS in patients with late onset relapsing-remitting MS 76
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 76
Multiple sclerosis patients preferences in decision making process 75
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab 75
Management of dysphagia in multiple sclerosis: current best practice 75
Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 74
Switching disease-modifying therapy in multiple sclerosis: escalation therapy has not an advantage on switching among same line drugs 74
Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer 73
WII may improve physical abilities in multiple sclerosis: a randomized single blind study 73
The association of CCSVI and MS is not a risk factor for cognitive impariment in MS 73
Prevalence of pain in multiple sclerosis: a multicenter italian study 73
Disability may influence patient willingness to partecipate in decision making on first-line therapy in multiple sclerosis 72
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019 71
Metal/metalloid levels in cerebrospinal fluid in the bulbar-and spinal-onset amyotrophic lateral sclerosis 71
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 71
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience 70
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 70
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 70
Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion 70
Treatment in worsening multiple sclerosis patients: new drugs are better than older ones? 70
Five insights from the Global Burden of Disease Study 2019 69
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 69
Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019 69
Untreated relapsing remitting multiple sclerosis (RR-MS) patients. A single centre exprerience 69
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 69
Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis 69
Identifying Cladribine prescription pattern in MS: an Italian multicentre study 68
Real-life impact of early interferonβ therapy in relapsing multiple sclerosis 68
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 68
Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide 68
Myeloid-derived Suppressor Cells and Multiple Sclerosis 67
Multidisciplinary approach of amyotrophic lateral sclerosis: a centre experience 67
Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life 67
Palliative care in progressive multiple sclerosis 66
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 66
Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 66
Dietary Phenolic Acids and Their Major Food Sources Are Associated with Cognitive Status in Older Italian Adults 65
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 65
Gender related side effects of interferon-beta treatment in multiple sclerosis patients 65
A multimodal approach to distinguish multiple sclerosis phenotypes at diagnosis using biomarker profiles 64
Oral drugs in multiple sclerosis therapy: An overview and a critical appraisal 64
MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study 62
Totale 8.342
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.017
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.017
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022888 0 0 1 0 363 30 14 47 97 93 21 222
2022/20232.663 270 115 199 121 48 210 16 182 1.373 45 52 32
2023/2024480 57 47 31 32 75 58 30 52 26 19 19 34
2024/20252.309 110 72 68 42 41 265 341 107 586 150 230 297
2025/20264.836 213 529 582 887 186 134 716 448 471 287 135 248
2026/2027407 143 264 0 0 0 0 0 0 0 0 0 0
Totale 11.613